Except the well‐established supportive clinical strategies for treating ALI and PF progression, recombinant CTSK peptides would be a valuable potency to directly target PF progression, however, should be precisely administrated determined by the serum concentration of CTSK abundance, which could be further evaluated in the future study. This evidence concerns the gene CTSK and acute respiratory distress syndrome.